Search the Community

Baseline use of hydroxychloroquine (HCQ) in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. These efficacy data establish that patients with lupus on baseline therapy with HCQ are not universally protected from COVID-19. BMJ Journals, Ann rheumatologist Dis, 05/07/2020. (Also see Treatments for Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Successful treatment with hydroxychloroquine for systemic lupus erythematosus with cutaneous involvement accompanied by a xanthomatous reaction. As yet unrecognized factors may play a role in the development of a xanthomatous reaction in discoid lupus erythematosus. PubMed, Lupus, 2019 Dec 1:961203319890677. (Also see Treatments for Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Belimumab alters transitional B-cell subset proportions in patients with stable systemic lupus erythematosus. We show that Belimumab-mediated B-cell activating factor depletion reduces the Transitional 2 subset in patients. PubMed, Lupus, 2019 Oct;28(11):1337-1343. (Also see Treatments for Lupus and Clinical Trials) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Early–stage predictors for treatment responses in patients with active lupus nephritis (LN). The change percentage of urinary protein-to-creatinine ratio >59% and the serum albumin >32.9g/l at the third month were valuable for predicting remission at the sixth month in LN. PubMed, Lupus. 2019 Mar;28(3):283-289. (Also see Treatments for Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Lupus nephritis and B–cell targeting therapy. The combination of different targeted approaches as well as a focus on new clinical end–points may be strategies to identify new therapeutic options. PubMed, Expert Rev Clin Immunol, 08/11/2017. (Also see Treatments for Lupus and B Cells and T Cells) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus (SLE) Receiving Immunosuppressive Medications. In a nationwide longitudinal study of Medicaid SLE patients at high risk of infection, rates of serious infection and mortality did not differ among new users of mycophenolate mofetil, azathioprine, or cyclophosphamide. PubMed, Arthritis Rheumatol, 2017 Feb;69(2):387-397. (Also see Treatments for Lupus) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.